Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers.
MDSCs
PD1/PD-L1 signaling
TAMs
TANs
Tregs
anti-PD1 Abs
chemokines
soluble CD163
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
22 07 2020
22 07 2020
Historique:
received:
26
05
2020
revised:
18
07
2020
accepted:
20
07
2020
entrez:
26
7
2020
pubmed:
28
7
2020
medline:
9
3
2021
Statut:
epublish
Résumé
Tumor-associated macrophages (TAMs) have been detected in most skin cancers. TAMs produce various chemokines and angiogenic factors that promote tumor development, along with other immunosuppressive cells such as myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs) and tumor-associated neutrophils. TAMs generated from monocytes develop into functional, fully activated macrophages, and TAMs obtain various immunosuppressive functions to maintain the tumor microenvironment. Since TAMs express PD1 to maintain the immunosuppressive M2 phenotype by PD1/PD-L1 signaling from tumor cells, and the blockade of PD1/PD-L1 signaling by anti-PD1 antibodies (Abs) activate and re-polarize TAMs into immunoreactive M1 phenotypes, TAMs represent a potential target for anti-PD1 Abs. The main population of TAMs comprises CD163
Identifiants
pubmed: 32707850
pii: biom10081087
doi: 10.3390/biom10081087
pmc: PMC7464513
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 19cm0106434h0002
Pays : International
Références
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
Exp Dermatol. 2019 Aug;28(8):933-939
pubmed: 31001887
Front Oncol. 2018 Nov 19;8:530
pubmed: 30510916
J Immunol Res. 2015;2015:983698
pubmed: 26819959
Oncoimmunology. 2018 Feb 8;7(5):e1426517
pubmed: 29721394
Front Med (Lausanne). 2019 Sep 04;6:194
pubmed: 31552251
Eur J Immunol. 2019 Aug;49(8):1140-1146
pubmed: 31257581
J Inflamm (Lond). 2012 Nov 23;9(1):46
pubmed: 23176085
Dermatology. 2014;229(4):369-78
pubmed: 25401296
J Immunother. 2019 Sep;42(7):265-268
pubmed: 31145230
Front Med (Lausanne). 2019 Apr 26;6:86
pubmed: 31080803
Cancer Res. 2006 Jan 15;66(2):1123-31
pubmed: 16424049
Front Immunol. 2019 Jul 25;10:1611
pubmed: 31402908
Cell Death Dis. 2019 Aug 8;10(8):598
pubmed: 31395859
Front Med (Lausanne). 2019 Jul 31;6:174
pubmed: 31417907
Dermatology. 2013;227(1):78-82
pubmed: 24008930
Clin Cancer Res. 2020 Jul 15;26(14):3831-3842
pubmed: 32332012
J Oncol Pharm Pract. 2020 Apr;26(3):758-760
pubmed: 31382865
J Am Acad Dermatol. 2012 Aug;67(2):215-25
pubmed: 22050913
Front Immunol. 2018 Sep 25;9:2159
pubmed: 30319622
J Leukoc Biol. 2016 Dec;100(6):1273-1284
pubmed: 27601624
Oncogenesis. 2019 Feb 22;8(3):17
pubmed: 30796203
Sci Transl Med. 2015 Mar 18;7(279):279ra41
pubmed: 25787767
Pigment Cell Melanoma Res. 2012 Jul;25(4):493-505
pubmed: 22498258
Curr Probl Cancer. 2017 Nov - Dec;41(6):407-412
pubmed: 29096940
Eur J Cancer. 2019 Apr;111:38-49
pubmed: 30822683
Mol Immunol. 2010 Apr;47(7-8):1650-60
pubmed: 20299103
J Am Acad Dermatol. 2020 Jan 10;:
pubmed: 31931083
Front Immunol. 2019 May 22;10:1147
pubmed: 31191529
Nat Immunol. 2018 Dec;19(12):1319-1329
pubmed: 30397348
Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):289-312
pubmed: 30703432
Cancers (Basel). 2019 Apr 19;11(4):
pubmed: 31010242
Cancer Sci. 2019 Jul;110(7):2080-2089
pubmed: 31102428
J Dermatol Sci. 2016 Sep;83(3):182-9
pubmed: 27342040
J Dermatol. 2018 Jun;45(6):735-737
pubmed: 29488243
Trends Immunol. 2016 Jan;37(1):41-52
pubmed: 26700397
J Clin Invest. 2018 Dec 3;128(12):5505-5516
pubmed: 30260323
Cancer Immunol Res. 2018 Mar;6(3):267-275
pubmed: 29362221
J Invest Dermatol. 2010 Oct;130(10):2412-22
pubmed: 20555352
Cell Rep. 2016 May 31;15(9):2000-11
pubmed: 27210762
Cancer Sci. 2018 Dec;109(12):3826-3839
pubmed: 30259595
Exp Dermatol. 2017 Dec;26(12):1193-1198
pubmed: 27501402
Clin Exp Dermatol. 2009 Oct;34(7):793-9
pubmed: 19438554
Hepatology. 2016 Sep;64(3):797-813
pubmed: 27228567
Oncoimmunology. 2015 May 26;4(11):e1047584
pubmed: 26451326
EMBO Mol Med. 2017 Jan;9(1):27-45
pubmed: 27932444
J Invest Dermatol. 2015 Oct;135(10):2547-2550
pubmed: 26016897
J Exp Med. 2010 Oct 25;207(11):2439-53
pubmed: 20876310
Clin Cancer Res. 2019 Nov 15;25(22):6614-6622
pubmed: 31455681
Front Immunol. 2019 Aug 07;10:1858
pubmed: 31440247
Cancer Immunol Res. 2018 Dec;6(12):1459-1471
pubmed: 30209062
J Invest Dermatol. 2011 Jun;131(6):1322-30
pubmed: 21307877
Curr Oncol Rep. 2020 Mar 21;22(4):39
pubmed: 32200442
J Invest Dermatol. 2019 Jan;139(1):186-194
pubmed: 30009831
Cancer Res. 2017 Oct 15;77(20):5628-5638
pubmed: 28904063
Oncotarget. 2017 Apr 13;8(41):71181-71187
pubmed: 29050354
Cancer Immunol Immunother. 2017 Aug;66(8):1015-1023
pubmed: 28382399
J Exp Med. 2015 Sep 21;212(10):1571-87
pubmed: 26347473
JAMA Dermatol. 2016 Apr;152(4):419-28
pubmed: 26762219
Oncotarget. 2018 Feb 15;9(21):15542-15551
pubmed: 29643991
J Cell Physiol. 2019 May;234(5):5700-5721
pubmed: 30378106
Clin Cancer Res. 2016 Feb 15;22(4):886-94
pubmed: 26446948
Nature. 2015 Jun 18;522(7556):345-348
pubmed: 25822788
Front Oncol. 2020 Feb 07;10:109
pubmed: 32117758
J Immunother Cancer. 2018 Aug 31;6(1):84
pubmed: 30170629
Front Immunol. 2018 Jun 11;9:1310
pubmed: 29942309
Immunity. 2017 Aug 15;47(2):284-297.e5
pubmed: 28813659
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Br J Dermatol. 2018 Jul;179(1):213-215
pubmed: 29405254
Br J Cancer. 2019 Jan;120(1):16-25
pubmed: 30413826
Proc Natl Acad Sci U S A. 2015 May 12;112(19):6140-5
pubmed: 25918390
Front Oncol. 2018 Jan 23;8:3
pubmed: 29410946
Oncogenesis. 2018 May 25;7(5):41
pubmed: 29799520
Nat Commun. 2019 Sep 3;10(1):3974
pubmed: 31481662
Exp Dermatol. 2016 Feb;25(2):107-12
pubmed: 26441016
Br J Dermatol. 2020 May;182(5):1214-1220
pubmed: 31361026
Cancer. 2010 Apr 1;116(7):1757-66
pubmed: 20143437
J Dermatol. 2020 Apr;47(4):356-362
pubmed: 31984569
Clin Ther. 2019 Jan;41(1):59-67
pubmed: 30528047
Clin Transl Oncol. 2020 Jul;22(7):1059-1066
pubmed: 31696413
Int J Cancer. 2014 Mar 15;134(6):1346-58
pubmed: 24154944
Front Med (Lausanne). 2019 Jun 26;6:140
pubmed: 31297373
Eur J Immunol. 2018 Mar;48(3):532-542
pubmed: 29120053
Aging (Albany NY). 2019 Oct 10;11(19):8623-8641
pubmed: 31600735
JCI Insight. 2019 Mar 7;4(5):
pubmed: 30720466
Br J Cancer. 2016 Feb 2;114(3):256-61
pubmed: 26794281
Clin Dev Immunol. 2011;2011:565187
pubmed: 22162712
Nat Immunol. 2017 Jan;18(1):64-73
pubmed: 27869817
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Cancer Res. 2008 Jul 1;68(13):5439-49
pubmed: 18593947
Nat Immunol. 2019 Jun;20(6):724-735
pubmed: 30936494
Int J Cancer. 2017 Feb 1;140(3):686-695
pubmed: 27756099
Nat Commun. 2019 Jun 11;10(1):2416
pubmed: 31186412
Br J Dermatol. 2020 May;182(5):1297-1300
pubmed: 31746456
Trends Immunol. 2015 Feb;36(2):63-70
pubmed: 25582039
Cancer Res. 2015 Sep 15;75(18):3771-87
pubmed: 26206559
J Dermatol. 2017 Mar;44(3):e13-e14
pubmed: 27440178
J Invest Dermatol. 2012 Apr;132(4):1239-46
pubmed: 22189788